topic

1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
Shiraj Sen, Justin Call, Kyriakos Papadopoulos, FD Smith, Edward H van der Horst

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1755; DOI: 10.1136/jitc-2023-SITC2023.1532
1533 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: efficacy and safety results from the open-label phase 2 SCOPE trial
Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare Barlow, Robert Miller, Fayaz Master, Lindy Durrant

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1756; DOI: 10.1136/jitc-2023-SITC2023.1533
1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial
Sapna P Patel, Richard Carvajal, Kamaneh Montazeri, Sunil Reddy, Jose Lutzky, Shaheer A Khan, Bartosz Chmielowski, Shailender Bhatia, Theresa Medina, Cara Haymaker, Rahul Sheth, Joshua D Kuban, Lindsay Thornton, Eric Wehrenberg-Klee, Paula Novelli, Anthony Lucci, Vanessa Sarli, Salyna Meas, Bryan Cox, Jason LaPorte, Prajna Guha, Chandra C Ghosh, Ann-Marie Hulstine, Robert Knight, Ashley Moody, David Geller, Steven Katz, Marlana Orloff, Diwakar Davar

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1757; DOI: 10.1136/jitc-2023-SITC2023.1534
1535 DECOSTAR^TM, a novel platform for TNF receptor superfamily agonism
Dulce Alvarado, Wojciech Bartkowski, Rakesh Verma, Mickey Pentecost

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1758; DOI: 10.1136/jitc-2023-SITC2023.1535
1536 Egfl6 induces IL-10 and CXCL2 in tumor associated myeloid cells: link to anti-tumor immunosuppression and resistance to anti-PD-L1 therapy in ovarian cancer
Sarah Sinno, Shoumei Bai, Claudia Coronnello, Linan Zhang, Hatice Osmanbeyoglu, Ronald Buckanovich, Sandra Cascio

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1759; DOI: 10.1136/jitc-2023-SITC2023.1536
1537 Androgen blockade primes NLRP3 inflammasome in macrophages to induce tumor cell phagocytosis
Kiranj Chaudagar, Srikrishnan Rameshbabu, Shenglin Mei, Taghreed Hirz, Zheng Xia, Ya-Mei Hu, Anna Argulian, Brian Labadie, Kunal Desai, Sammy Grimaldo, Doga Kahramangil, Rishikesh Nair, Sabina DSouza, Dylan Zhou, Jordan Shafran, David Sykes, Amy Moran, Akash Patnaik

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1760-A1762; DOI: 10.1136/jitc-2023-SITC2023.1537
1538 Cytokine checkpoint discovery in human NK cells
Iva Nikolic, Joe Cursons, Benjamin Shields, Stephane Chappaz, Nicholas D Huntington

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1763; DOI: 10.1136/jitc-2023-SITC2023.1538
1539 SARS-CoV-2 genome-wide single-chain-trimer peptide-MHCs reveal CD8+ T cell landscape in COVID-19 patients and distinct TCR repertoire dynamics
Jingyi Xie, James Heath

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1764; DOI: 10.1136/jitc-2023-SITC2023.1539
1540 Age-associated NAD decline impairs mitochondrial fitness and function of CAR-T cells
Helen Carrasco Hope, Jana de Sostoa, Pierpaolo Ginefra, Yi-Hsuan Chiang, Cristina Jimenez Luna, Jesús Corria Osorio, George Coukos, Denis Migliorini, Nicola Vannini

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1765; DOI: 10.1136/jitc-2023-SITC2023.1540
222-A The beacon® optofluidic system enables multi-functional characterization of T cells and sequential recovery of single cells from co-culture for downstream transcriptomic analysis
Long Le, Mick Phillips, Matthew Jemielita, Ritika Kukreja, Eric Sackmann, Aribet De Jesus

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1767; DOI: 10.1136/jitc-2023-SITC2023.0222-A

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages